HCA Healthcare (NYSE:HCA) Issues FY 2025 Earnings Guidance

HCA Healthcare (NYSE:HCA) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of 27.000-28.000 for the period, compared to the consensus EPS estimate of 26.280. The company issued revenue guidance of $75.0 billion-$76.5 billion, compared to the consensus revenue estimate of $75.0 billion.

HCA Healthcare Stock Performance

Shares of HCA stock opened at $446.58 on Friday. HCA Healthcare has a fifty-two week low of $289.98 and a fifty-two week high of $461.56. The stock has a 50 day moving average price of $414.84 and a two-hundred day moving average price of $381.67. The company has a market capitalization of $104.50 billion, a P/E ratio of 18.77, a PEG ratio of 1.39 and a beta of 1.40.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings data on Friday, October 24th. The company reported $6.96 earnings per share for the quarter, beating the consensus estimate of $5.64 by $1.32. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.The firm had revenue of $19.16 billion during the quarter, compared to the consensus estimate of $18.55 billion. During the same quarter in the previous year, the company posted $4.90 earnings per share. The business’s revenue was up 9.6% on a year-over-year basis. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. As a group, equities analysts predict that HCA Healthcare will post 24.98 earnings per share for the current year.

HCA Healthcare Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 29th. Investors of record on Monday, December 15th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, December 15th. HCA Healthcare’s dividend payout ratio is currently 12.11%.

Analyst Upgrades and Downgrades

HCA has been the subject of a number of recent analyst reports. UBS Group upped their target price on HCA Healthcare from $438.00 to $495.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Wolfe Research downgraded HCA Healthcare from an “outperform” rating to a “peer perform” rating in a report on Monday, July 28th. KeyCorp increased their price objective on HCA Healthcare from $370.00 to $465.00 and gave the stock an “overweight” rating in a report on Wednesday, October 8th. Barclays increased their price objective on HCA Healthcare from $390.00 to $445.00 and gave the stock an “overweight” rating in a report on Thursday, September 18th. Finally, Morgan Stanley decreased their price objective on HCA Healthcare from $410.00 to $400.00 and set an “equal weight” rating for the company in a report on Monday, July 28th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, HCA Healthcare has an average rating of “Moderate Buy” and a consensus price target of $437.19.

Insider Activity at HCA Healthcare

In other news, EVP Michael S. Cuffe sold 3,836 shares of HCA Healthcare stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the transaction, the executive vice president directly owned 31,503 shares of the company’s stock, valued at $13,194,716.52. The trade was a 10.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HCA. Viking Global Investors LP grew its stake in shares of HCA Healthcare by 58.5% during the 2nd quarter. Viking Global Investors LP now owns 1,872,133 shares of the company’s stock valued at $717,214,000 after acquiring an additional 690,773 shares during the period. Abdiel Capital Advisors LP grew its stake in shares of HCA Healthcare by 35.5% during the 2nd quarter. Abdiel Capital Advisors LP now owns 646,222 shares of the company’s stock valued at $247,568,000 after acquiring an additional 169,201 shares during the period. Balyasny Asset Management L.P. grew its stake in shares of HCA Healthcare by 634.0% during the 2nd quarter. Balyasny Asset Management L.P. now owns 123,219 shares of the company’s stock valued at $47,205,000 after acquiring an additional 146,295 shares during the period. Alliancebernstein L.P. grew its position in shares of HCA Healthcare by 13.8% during the second quarter. Alliancebernstein L.P. now owns 600,248 shares of the company’s stock worth $229,955,000 after purchasing an additional 72,795 shares in the last quarter. Finally, Sei Investments Co. grew its position in shares of HCA Healthcare by 56.3% during the second quarter. Sei Investments Co. now owns 136,589 shares of the company’s stock worth $52,328,000 after purchasing an additional 49,214 shares in the last quarter. 62.73% of the stock is currently owned by institutional investors.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.